 |
ImmunoGen, Inc. Announces that sanofi-aventis Has Entered into an Option Agreement for Expanded Access to the Company's TAP Technology
Dec 26, 2006
|
9.4 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 26, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced that sanofi-aventis has entered into an
option agreement that enables it to gain expanded access to the
Company's Tumor-Activated Prodrug (TAP) technology. Sanofi-aventis
currently has rights to use the technology with antibodies to the
targets tha...
|
|
ImmunoGen, Inc. Announces Presentation of First Clinical Data for Genentech's Trastuzumab-MCC-DM1
Dec 15, 2006
|
9.1 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 15, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) announced the presentation today of the initial
findings from a Phase I clinical study that evaluates Genentech's
trastuzumab-MCC-DM1 for the treatment of HER2-positive metastatic
breast cancer. Trastuzumab-MCC-DM1 is being developed by Genentech and
uses ImmunoGe...
|
|
ImmunoGen, Inc. Announces Presentation at ASH of Encouraging Findings with HuN901-DM1 for the Treatment of Multiple Myeloma
Dec 11, 2006
|
11.0 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 11, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) announced the presentation today of encouraging initial
findings from a Phase I study evaluating the Company's huN901-DM1
Tumor-Activated Prodrug (TAP) compound for the treatment of multiple
myeloma at the annual meeting of the American Society of Hematology
(ASH)...
|
|
ImmunoGen, Inc. Announces Webcast of Panel Session at the 2006 RBC Capital Markets Healthcare Conference
Dec 6, 2006
|
6.8 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 6, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced that Mitchel Sayare, Chairman and CEO
of the Company, will participate on the panel, Cancer Antibodies:
Developing a Pipeline, at the 2006 RBC Capital Markets Healthcare
Conference. This 55-minute panel session will begin at 11:00 a.m. EST
on Decemb...
|
|
ImmunoGen, Inc. Announces Webcast of Presentation at the Lazard Capital Markets Third Annual Life Sciences Conference
Nov 21, 2006
|
6.8 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 21, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced that its presentation at the Lazard
Capital Markets Third Annual Life Sciences Conference will be webcast
live. The 25-minute presentation is scheduled to begin at 11:30 a.m.
EST on November 28, 2006, and will be given at the New York Palace
Hotel ...
|
|
ImmunoGen, Inc. Announces Presentation of HuN901-DM1 Clinical Data At EORTC-NCI-AACR Conference Showing Compound is Well Tolerated and Demonstrates Anticancer Activity
Nov 10, 2006
|
10.5 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 10, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced the presentation of clinical data from
a Phase I study evaluating the Company's huN901-DM1 anticancer agent
for the treatment of small-cell lung cancer (SCLC) and other
CD56-expressing solid tumors. The compound has been found to be well
tolerated....
|
|
ImmunoGen, Inc. Announces Presentation of HuC242-DM4 Clinical Data at EORTC-NCI-AACR Conference
Nov 8, 2006
|
9.7 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced the presentation of initial clinical
data from an ongoing Phase I study evaluating the Company's huC242-DM4
compound for the treatment of colorectal, pancreatic, gastric and
other CanAg-expressing cancers.
This trial is being conducted at...
|
|
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2007 Financial Results
Nov 2, 2006
|
15.6 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 2, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN), a biopharmaceutical company that develops targeted
anticancer therapeutics using its Tumor-Activated Prodrug (TAP)
technology, today announced financial results for the three-month
period ended September 30, 2006 - the first quarter of the Company's
2007 fiscal ye...
|
|
ImmunoGen, Inc. Announces Webcast of Presentation at the Cowen & Co. 7th Annual Global Health Care Conference
Nov 1, 2006
|
6.7 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 1, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced that its presentation at the Cowen &
Co. 7th Annual Global Health Care Conference will be webcast live. The
presentation is scheduled to begin at 4:10 p.m. GMT (11:10 a.m. EST)
on November 8, 2006, and will be given at The Landmark London Hotel i...
|
|
ImmunoGen, Inc. Announces Conference Call to Discuss Its First Quarter Fiscal Year 2007 Financial Results
Oct 26, 2006
|
6.7 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 26, 2006--ImmunoGen, Inc.
(Nasdaq:IMGN) will host a conference call at 4:30 pm (ET) on Thursday,
November 2, 2006. The call will include management discussion of
financial results and provide an update on ImmunoGen.
To access the live call by phone, dial 913-981-4900. No passcode
is required. ...
|
|
sanofi-aventis Licenses Broader Access to ImmunoGen's Antibody Humanization Technology
Oct 18, 2006
|
8.1 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 18, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced that sanofi-aventis has licensed
non-exclusive rights to use ImmunoGen's proprietary resurfacing
technology to humanize antibodies.
"We're delighted that sanofi-aventis has moved to secure their
access to our humanization technology,"...
|
|
ImmunoGen, Inc. Announces Webcast of its Presentation at the BIO Investor Forum 2006
Oct 12, 2006
|
6.7 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 12, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced that its presentation at the BIO
Investor Forum 2006 will be webcast live. The presentation is
scheduled to begin at 12:00 pm PT (3:00 pm ET) on Wednesday, October
18, 2006, and will be given at the Palace Hotel in San Francisco, CA.
The presentati...
|
|
ImmunoGen Announces Initiation of Clinical Testing of AVE1642 Anticancer Compound in Collaboration with sanofi-aventis
Oct 4, 2006
|
8.1 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 4, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced that sanofi-aventis has initiated
clinical testing of AVE1642, a therapeutic antibody that binds to the
Insulin-like Growth Factor 1 Receptor (IGF-1R). This event triggers a
$2 million milestone payment to ImmunoGen. AVE1642 is an anticancer
compoun...
|
|
ImmunoGen, Inc. Announces that sanofi-aventis Has Extended the Term of its Research Collaboration with the Company; ImmunoGen Also Gains More Flexibility to Expand Product Pipeline
Aug 31, 2006
|
9.7 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 31, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced that sanofi-aventis U.S. LLC has
exercised its right to extend the term of its research collaboration
with the Company. ImmunoGen now will receive committed research
support funding from sanofi-aventis through August 31, 2008. The
Company also anno...
|
|
ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2006 Financial Results; Company Provides Business Update
Aug 10, 2006
|
15.2 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 10, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN), a biopharmaceutical company that develops targeted
anticancer therapeutics using its Tumor-Activated Prodrug (TAP)
technology, today announced financial results for the three-month
period and fiscal year ended June 30, 2006.
"We've made considerable pr...
|
|
ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2006 Financial Results
Aug 3, 2006
|
7.0 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 3, 2006--ImmunoGen, Inc.
(Nasdaq:IMGN) will host a conference call at 4:30 p.m. EDT on
Thursday, August 10, 2006, to discuss the Company's financial results
for the quarter ended June 30, 2006 -- the fourth quarter of
ImmunoGen's 2006 fiscal year. Management also will provide an update
on the Company....
|
|
ImmunoGen, Inc. Grants Biotest AG Rights to Use ImmunoGen TAP Technology to Develop Novel Anticancer Therapeutics; ImmunoGen Has Opt-In Rights on Resulting Compounds
Jul 11, 2006
|
9.8 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 11, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) announced today that the Company has entered into an
agreement that grants Biotest AG exclusive rights to use ImmunoGen's
Tumor-Activated Prodrug (TAP) technology with antibodies targeting an
undisclosed target to develop novel anticancer therapeutics. Under the...
|
|
ImmunoGen, Inc. to Present at Needham & Company, LLC's Fifth Annual Biotechnology and Medical Technology Conference
Jun 8, 2006
|
6.7 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 8, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced that it will present at Needham &
Company, LLC's Fifth Annual Biotechnology and Medical Technology
Conference, which is scheduled to take place June 14 - 15, 2006 at the
New York Palace Hotel in New York City. The 25-minute presentation is
to be...
|
|
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2006 Financial Results; Company Provides Business Update
May 4, 2006
|
15.4 KB |
| |
CAMBRIDGE, Mass., May 04, 2006 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical
company that develops targeted anticancer therapeutics using its
Tumor-Activated Prodrug (TAP) technology, today announced financial
results for the three- and nine-month periods ended March 31, 2006 -
the third quarter and first nine months...
|
|
ImmunoGen, Inc. to Develop Commercial-Scale Manufacturing Process for Trastuzumab-DM1 for Genentech; Companies Also Amend 2000 Agreement for TAP Compounds Targeting HER2, Potentially Providing Increased Royalties and Milestones to ImmunoGen
May 4, 2006
|
8.8 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2006--ImmunoGen, Inc.
(Nasdaq: IMGN), a biopharmaceutical company that develops targeted
anticancer therapeutics using its Tumor-Activated Prodrug (TAP)
technology, today announced that the Company has entered into an
agreement to collaborate with Genentech to create a commercial
manufacturing proce...
|
|
|
